| Previous close | 10.30 |
| Open | 10.47 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 125.00 |
| Expiry date | 2024-07-19 |
| Day's range | 9.85 - 11.64 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Yahoo FinanceEli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Investor's Business DailyIBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.
BloombergOzempic Maker Novo Nordisk Has Denmark’s Economy Hooked
(Bloomberg) -- There is no escaping Ozempic and Wegovy. The diabetes and obesity drugs are a global phenomenon. They’ve won over the rich and famous, generated billions in sales and blown open a new market for weight loss drugs, which Goldman Sachs estimates will reach $100 billion a year by 2030.Most Read from BloombergTesla Axes Most of Supercharger Team in Blow to Other AutomakersTraders Expect Biggest Fed-Day Move in S&P Since 2023, Citi SaysWall Street Hit by Fed Jitters to Close Wild April
